MedTrace Logo

Intranasal Vasopressin Treatment in Children With Autism

NCT03204786 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2025-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.

Conditions

Interventions

DRUG

Vasopressin (USP) Injectable Solution [Vasostrict]

Nasal Spray

DRUG

Placebo

Placebo Nasal Spray

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Antonio Y. Hardan, M.D. · Stanford University

  • Karen J. Parker, Ph.D. · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2024-03-18
Completion
2024-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204786 on ClinicalTrials.gov